Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin. / Loft, Annika; Kjær, Andreas.

In: Ugeskrift for Laeger, Vol. 180, No. 46, V06180463, 2018.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Loft, A & Kjær, A 2018, 'Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin', Ugeskrift for Laeger, vol. 180, no. 46, V06180463. <http://ugeskriftet.dk/videnskab/nuklearmedicinsk-diagnostik-og-cancerpraecisionsmedicin>

APA

Loft, A., & Kjær, A. (2018). Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin. Ugeskrift for Laeger, 180(46), [V06180463]. http://ugeskriftet.dk/videnskab/nuklearmedicinsk-diagnostik-og-cancerpraecisionsmedicin

Vancouver

Loft A, Kjær A. Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin. Ugeskrift for Laeger. 2018;180(46). V06180463.

Author

Loft, Annika ; Kjær, Andreas. / Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin. In: Ugeskrift for Laeger. 2018 ; Vol. 180, No. 46.

Bibtex

@article{12313b40c58446d3b0691e584db4b65b,
title = "Nuklearmedicinsk diagnostik og cancerpr{\ae}cisionsmedicin",
abstract = "Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.",
author = "Annika Loft and Andreas Kj{\ae}r",
year = "2018",
language = "Dansk",
volume = "180",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "46",

}

RIS

TY - JOUR

T1 - Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

AU - Loft, Annika

AU - Kjær, Andreas

PY - 2018

Y1 - 2018

N2 - Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.

AB - Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.

M3 - Tidsskriftartikel

C2 - 30417816

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 46

M1 - V06180463

ER -

ID: 219536574